B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis
Open Access
- 1 January 2010
- journal article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 12 (2) , 112
Abstract
Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with diffuse cutaneous systemic sclerosis. A recent open-label trial provides further evidence showing marked effects of rituximab treatment on skin thickening, functional ability, and disease activity in conjunction with effects on lesional and circulating B cells and on interleukin-6 and BAFF (B-cell activating factor of tumor necrosis factor family). The excellent safety profile of rituximab in this and other trials warrants further well-designed clinical trials in larger patient groups combined with comprehensive biomarker studies.Keywords
This publication has 10 references indexed in Scilit:
- B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trialArthritis Research & Therapy, 2010
- Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximabRheumatology International, 2010
- Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological studyAnnals of the Rheumatic Diseases, 2010
- Is There a Role for B-cell Depletion as Therapy for Scleroderma? A Case Report and Review of the LiteratureSeminars in Arthritis and Rheumatism, 2009
- Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle studyRheumatology, 2009
- B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisArthritis & Rheumatism, 2009
- The role of B cells in systemic sclerosis2008
- Discordant response to rituximab in a systemic sclerosis patient with associated myositisJournal of the American Academy of Dermatology, 2008
- Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximabRheumatology, 2007
- Is Rituximab a Potential New Therapy in Systemic Sclerosis?JCR: Journal of Clinical Rheumatology, 2004